PMID: 6110344Mar 1, 1981Paper

Changing epidemiology of tardive dyskinesia: an overview

The American Journal of Psychiatry
D V Jeste, R J Wyatt

Abstract

Dyskinesia is found significantly more often among neuroleptic-treated psychiatric patients than among non-neuroleptic-treated patients. The epidemiology of tardive dyskinesia is changing; its reported prevalence among neuroleptic-treated psychiatric inpatients has been progressively rising and has reached 25% during the past five years. The prevalence of persistent tardive dyskinesia that may be attributable to neuroleptics is about 13%. Tardive dyskinesia is not restricted to old, brain-damaged inpatients but also occurs with a noticeable frequency among younger patients, including outpatients, treated neuroleptics. Yet neuroleptics are the most effective available treatment for schizophrenia; hence, any drastic curtailment of their use in the treatment of chronic schizophrenic patients may not be justified. Cautious use of these drugs, along with intensified research on tardive dyskinesia is warranted.

Citations

Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·J E KalachnikK M Slaw
Feb 1, 1985·Biological Psychiatry·H A NasrallahM McCalley-Whitters
Jun 1, 1988·Biological Psychiatry·S P MahadikS E Karpiak
Feb 1, 1986·Biological Psychiatry·T KolakowskaM A Reveley
Jan 1, 1983·Archiv für Psychiatrie und Nervenkrankheiten·M Bartels, J Themelis
Jan 1, 1981·Progress in Neuro-psychopharmacology·D RadonjicV Knott
Jan 1, 1987·Psychopharmacology·G EllisonJ Kinney
Jan 1, 1983·Psychopharmacology·B WistedtA Jørgensen
Jan 1, 1989·Psychopharmacology·W Z PotterW W Yan
Jan 1, 1982·Psychopharmacology·D V JesteR J Wyatt
Aug 1, 1983·Brain Research Bulletin·C Y Yung
May 1, 1982·Psychosomatics·M E WolfA D Mosnaim
Aug 1, 1982·Psychosomatics·K E CallenM I Sorkin
May 1, 1986·Biological Psychiatry·W F Gattaz, M Köllisch
Jan 1, 1987·Journal of Chronic Diseases·H MorgensternS Holmberg
Sep 1, 1985·Public Health Nursing·A L WhallJ Ager
Jan 1, 1995·International Journal of Psychiatry in Medicine·M Sajatovic, L Ramirez
Mar 1, 1991·The Australian and New Zealand Journal of Psychiatry·C H Tan, L K Tay
Mar 7, 2014·Journal of Psychopharmacology·Maju M KoolaKatherine J Aitchison
Feb 1, 1982·Psychological Medicine·R M Ridley, H F Baker
Apr 18, 2003·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·H TonelliR Andreatini
Aug 1, 1983·Brain Research Bulletin·A J Blowers, R L Borison
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·P Deniker
Jun 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·W M GlazerJ T Doucette
Nov 1, 1986·The British Journal of Psychiatry : the Journal of Mental Science·J L Waddington, H A Youssef
Jun 1, 1982·The British Journal of Psychiatry : the Journal of Mental Science·R G McCreadieG S Winslow
Oct 1, 1989·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·X FornazzariM V Seeman
Jan 1, 1989·The Journal of International Medical Research·M Lader
May 1, 1982·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes, T Trauer
Jul 1, 1994·Cranio : the Journal of Craniomandibular Practice·S KaiH Tashiro
Feb 1, 1989·Journal of Mental Deficiency Research·R K StoneG Ellman
Feb 1, 1983·Psychological Medicine·T R BarnesS M Gore
Jun 1, 1994·The Australian and New Zealand Journal of Psychiatry·A ManderN Christophidis
Jan 1, 1994·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·A Piper
Jul 1, 1983·Drug Intelligence & Clinical Pharmacy·S S WeberP Mastrati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here